The Department of Molecular Imaging & Theranostics conducts research on diagnostics using molecular imaging and its applications in treatment. Molecular imaging is a quantum science technology that visualizes various biological phenomena at the molecular level within the body without causing harm. Diagnostic methods such as PET and MRI, which utilize this technology, have been widely applied in clinical settings. Recently, a new medical approach called "theranostics"—the fusion of diagnosis and therapy—has gained global attention. With this concept of integrating diagnosis and treatment as a central theme, we aim to advance personalized medicine by applying molecular imaging diagnostics to therapeutic strategies. Our research and development efforts, primarily focused on cancer, span a wide range of fields including basic research, medical-engineering collaborative studies, preclinical research, and clinical application studies. These efforts utilize technologies such as PET, MRI, and radioisotopes.
Mobile, Compact, Access-friendly Therapy: “MCAT” is now available!
MCAT(Mobile Controlled Area for TRT) is a medical facility for targeted radionuclide cancer therapy. It is based in a trailer that can be easily moved to any hospital. The alpha-emitter 225Ac was approved by the Nuclear Regulation Authority on June 30, 2022, so therapy with alpha-emitting 225Ac-radiotherapeutic agents is now available. We shall soon be conducting clinical trials with MCAT. The ultimate goal is to make cutting-edge cancer therapy accessible to everyone in need.
organization
Higashi Tatsuya Director
Research Group
- Diagnostic and Therapeutic Nuclear Medicine Group(Takahashi Miwako)
- Applied MRI Research Group(Obata Takayuki)
- Experimental Nuclear Medicine Group(Tsuji Atsushi)
- Functional and Molecular Imaging Group(Osada Kensuke)
Links